Bavarian Nordic has increased its 2025 revenue guidance due to strong performance in its travel health and public preparedness businesses. H1 revenue reached DKr3bn, up 33% from last year. Travel health business saw a 24% growth, driven by demand for rabies and TBE vaccines.

However, weaker revenue was noted for cholera and typhoid vaccines, with sales declining for Vaxchora and Vivotif in H1. Sales for the public preparedness business rose by 51% to DKr1.5bn due to quarterly phasing of vaccine orders.

As a result of the positive performance, Bavarian Nordic has raised its full-year revenue expectations to DKr6bn-DKr6.6bn. The company also sold a priority review voucher for $160m, boosting cash reserves.

Bavarian Nordic faces a potential takeover offer from a consortium valuing the company at around DKr19bn. Shareholders will vote on the offer, which could take the company private pending approval.

The company has seen success in 2025 with the approval of its chikungunya vaccine Vimkunya and freeze-dried smallpox and mpox vaccines. CEO Paul Chaplin anticipates the chikungunya vaccine to be a valuable asset in the travel health portfolio.

Read more at Yahoo Finance: Bavarian Nordic boosts 2025 guidance as takeover offer looms